Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers
can visit their reader profile
to add Endpoints Weekly. New to Endpoints?
Sign up here
.
Drew Armstrong has officially joined the Endpoints team. We are thrilled to welcome him and excited for his new vision. If you have any feedback or thoughts, don’t hesitate to reach out. You can reply to this email to reach an editor.
Biogen, Seagen lock in CEOs
Two high-profile biotech CEO searches coincidentally culminated in appointments on the same day.
Chris
Viehbacher
, the former CEO of
Sanofi
,
will become
Biogen’s
next leader. He steps into
Michel Vounatsos’
shoes at a tumultuous moment sandwiched between a controversial Alzheimer’s drug launch and a promising one.
Seagen
, meanwhile,
tapped
David Epstein
of
Novartis
fame to steer the ship in the wake of
Clay Siegall’s
sudden resignation.
2022 so far — by the numbers
This year, with Nasdaq iced over, everything is falling behind. We asked
DealForma
chief
Chris Dokomajilar
to do a special 10-month run of the numbers to
give us a clearer picture of where we’re headed
in a stressful 2022, and you can see the cracks widening in almost every key spot. It is important to note, though, that with the inevitable end of the pandemic boom, we’re still seeing historically high rates of investing. But silver linings are few and far between.
Pharma on Twitter
As
Elon Musk’s
takeover of Twitter — and almost-daily controversies — causes confusion and consternation,
Eli Lilly
got swept up in the chaos
. Amid an overhaul of the site’s verification system, the pharma giant became a target for impersonation, with a fake Lilly Twitter account posting a message pretending the company had made insulin completely free. Meanwhile, other pharma advertisers on the platform
are also trying to figure out what to do
.
Flagship stems the breach
Eighteen months after
Repertoire Immune Medicines
unveiled a whopping $189 million raise, the company confirmed that
it has laid off 65 staffers
, or close to half the employee roster.
Flagship Pioneering,
which founded the startup, is sending in one of its senior partners to pick up the pieces. And
Torben Straight
Nissen
, who took the president’s job at struggling
Rubius
, has some experience with setbacks. Repertoire hasn’t mentioned what has gone wrong, just that it plans to devote itself to its platform for immune medicines.
PREMIUM
Phase III bound
Serial biotech entrepreneur
Lonnie Moulder
has scored some big wins along the way, most notably the $9 billion he racked up selling
MGI
and
Tesaro
. And now the new startup he’s helping manage as executive chair is making a
bold move into Phase III
— damn the market turmoil that has largely iced IPOs.
Zenas
BioPharma
, based in Waltham, MA with staffers primarily in the US with some clinical ops in China, put together a $118 million round to fund the trial for
obexelimab
, a drug it got from
Xencor
last fall with a mix of equity and milestones.
Chat with Altos Labs
A few weeks ago, Endpoints founder and editor John Carroll had a chance to sit down with
Rick Klausner
and
Hal Barron
to discuss in some depth about their startup
Altos Labs
, which is using some very deep-pocket backing to establish an institute of their own to go after cell rejuvenation. You can
now read the transcript to hear their thoughts directly
.
Fungi mining draws backing
SoftBank
-backed
Hexagon
Bio
, which is mining fungi to find new drugs for cancer and infectious diseases, is raising another round of financing, Endpoints News learned. It has so far raised $67 million in a new round, but the total offering could eventually go beyond that figure,
to almost $80 million
.
PEOPLE
Depressed by the market, another handful of biotechs
brought down the axe
.
Sumitomo Pharma
is laying off 360 employees at its
Sunovion
unit;
Nabriva
is chopping about 40% of its workforce to focus on a treatment for its acute bacterial skin and skin structure infections; and vaccine manufacturer
Valneva
is shrinking its headcount by 20% to 25% in the wake of a setback on its Covid-19 shot that forced it to resize.
Adaptimmune
has a bitter pill to swallow after
GSK
axed its partnership in late October, coming in the form of a reorganization and budget cuts. Citing a need to prioritize certain high-value programs during challenging economic times, the TCR biotech says it
will let go of 25% to 30% of employees
as it limits resources for non-core programs.
Clovis Oncology’s
rocky 13-year run from startup developer to commercialization — while surviving accusations of playing fast and loose with the data — may be coming to a close. The biotech disclosed that it is on course to run out of cash in a matter of weeks and
may have no alternative but to file for bankruptcy
. As cash dwindled, it laid off 115 staffers.
Now that it’s gotten both clinical holds lifted for the blood cancer drug
emavusertib
,
Curis
is ready to move full speed ahead. But first, it’s going to prune the pipeline — with a wave of layoffs to follow. As a result of reallocating resources and deprioritizing other programs, the biotech
is shrinking the workforce by 30%
.
R&D
Two years after an accelerated approval,
GSK’s
BCMA-targeting antibody-drug conjugate
flunked a confirmatory Phase III study
in multiple myeloma, raising doubts about the pharma giant’s plan to move it up to earlier lines of treatment in a crowded space. Pitted head-to-head trial against a standard of care combo dubbed
PomDex
,
Blenrep
failed the primary endpoint of progression-free survival.
Amgen
may be way late to the obesity game, but judging from the analysts’ response to its snapshot of early-stage data, the market scouts are still loving the blockbuster potential of
AMG 133
. An update at AHA for its anti-GIPR/GLP-1 peptide conjugate
enjoyed warm reception and comments
that it looks “solidly competitive,” setting the stage for full data in a few weeks.
Norbert Bischofberger
went back to his old colleagues at
Gilead
to pluck an AML drug off its back shelves and put it into the late-stage pipeline at
Kronos
. But after working out a shorter Phase III path for the SYK inhibitor using a unique primary endpoint,
he’s pulling the plug on the trial
, beleaguered by a host of issues relating to enrollment.
At the annual Liver Meeting,
GSK
unveiled results from a Phase II trial
on its hepatitis B treatment, which it said earlier this year could “lead to a functional cure” for the liver infection. While not quite hitting a home run, the program lead described the drug as hitting first base — paving the way for future combinations.
During his Q3 earnings call,
Amgen
CEO
Bob Bradway
touted a cardio program called
olpasiran
as one of the top drugs in the pipeline. Days later, the pharma giant took the wraps off a detailed and updated outline of Phase II data as it
explained its hopes
for a siRNA drug designed to wipe out lipoprotein(a) levels in patients suffering from atherosclerotic cardiovascular disease.
CG Oncology
has been quietly chugging along — only giving updates at sequential cancer conferences ahead of a full readout on its oncolytic virus cancer therapy next year. In its latest at SITC, the Irvine, CA-based biotech showed up with
longer-term data
on its therapy,
CG0070
, in combination with
Merck’s
Keytruda
.
Hovering around penny stock territory, New Jersey-based
Cyclacel Pharmaceuticals
is finally going to call it quits
on a
Daiichi
Sankyo
-partnered cancer drug candidate that saw a Phase III flop in acute myeloid leukemia in late 2014.
J&J
and
Idorsia
presented
new Phase III data
for their hypertension drug,
aprocitentan
, breaking down how it reduced blood pressure by a statistically significant margin and maintained its effect for up to 48 weeks. Researchers were testing it in patients whose high blood pressure is tough to control and in combination with standard background therapies.
As
Roche
prepares to take a kidney disease drug into Phase III,
Ionis
revealed
new details on a Phase II trial
that pushed the pharma giant to acquire the full rights.
IONIS-FB-LRx
, an antisense compound, hit its primary endpoint in immunoglobulin A nephropathy. With the new data, Ionis spelled out reduction in urine protein excretion as well as kidney function.
Q3 EARNINGS
Just over a year ago, the FDA slapped
AstraZeneca
with a clinical hold on its MCL-1 inhibitor to look into safety information, putting the Phase I trial in limbo. The drug became one of three new molecular entities to be swept out of the early-stage pipeline
as part of AstraZeneca’s Q3 housecleaning
. The other two are a
Moderna
-partnered mRNA therapy for solid tumors and an antibody aimed at chronic kidney disease.
EQRx
placed a substantial bet it could shake up the US healthcare system, promising to bring a swath of fast-follow drugs priced substantially lower. But the business model appears to be unraveling as it decided its first effort — a PD-L1 inhibitor licensed from China’s
CStone
—
is no longer commercially viable in the US
. It also now plans to pursue “market-based pricing” for the two other clinical candidates.
As biotechs around the sector reported their third quarter earnings this week,
Xilio
Therapeutics
,
Protagonist Therapeutics
and
Evaxion Biotech
slimmed down their pipelines
and revealed program cuts, continuing the trend seen all year throughout the sector as companies felt the weight of the bear market.
While the impact of inflation, already some of the highest in decades, was not quite apparent in
Bayer’s
operations this year,
execs told investors and analysts
that they “expect the full cost inflation effects across the value chain to actually materialize” in 2023. They also offered an update on plans for
Eylea
, the top-selling
Regeneron
-partnered eye drug.
After getting off to a rather rocky start in July,
GSK’s
consumer health spinoff
Haleon
is
upping its full-year sales guidance
on the heels of what CEO
Brian McNamara
called a “strong quarter of growth.” The company attributes the growth to the roughly 12% uptick in oral health sales and solid respiratory figures as we enter cold and flu — and likely Covid — season.
LAW
The US Supreme Court
agreed to take up a long-running patent battle
between PCSK9 frontrunners
Amgen
and
Sanofi
that has spilled into a broader issue of how narrowly pharma patents should be written. Amgen filed the initial petition last November, claiming that a prior court ruling puts an impossible expectation on companies filing patents. Sanofi, on the other hand, argued that Amgen’s patents were overly broad.
On the other hand, SCOTUS
declined to hear
Bristol Myers Squibb’s
petition to revive a $1.2 billion verdict against
Gilead
, the latest setback in a years-long legal tussle that began with their respective subsidiaries,
Juno
and
Kite
. Bristol Myers had argued that an appeals court’s invalidation of its CAR-T patent “may threaten innovation.”
It’s been 16 years since
AstraZeneca’s
blockbuster asthma inhaler
Symbicort
came to market in the US, hauling in more than $13 billion over just the last five years and becoming the market leader in the class.
Viatri
, which earned approval earlier this year for the first generic,
just won a court case related to
an AstraZeneca patent on Symbicort, but that’s not the end of the road for Symbicort litigation.
The FTC is calling to keep strict statutory limits on Orange Book patent listings, explaining in an amicus brief that patents related to REMS distribution systems should not block generic or other competition. In particular,
it singled out
Jazz Pharma
for abusing the process, in response to
Avadel CNS Pharmaceuticals’
motion to delist one of Jazz’s patents relating to REMS.
A charity backed by a coalition of cancer drug manufacturers wants to provide financial assistance to Medicare Part D patients dealing with expensive cancer drugs. But HHS insists that any monetary help would be a violation of anti-kickback laws. To fight that decision, the nonprofit charity
filed suit in Virginia district court
, saying the HHS was arbitrary and capricious in this decision.
Just one month after the news that
Teva
and
Eli Lilly
were going to duke it out in federal court for patent infringement, a jury in Massachusetts ruled that Eli Lilly has to pay Teva a
combined $176.5 million
on three types of damages. Teva, which markets the migraine treatment
Ajovy
, sued Lilly over its rival drug,
Emgality
.
CORONAVIRUS
The EMA
offered a positive recommendation
for the first protein-based adjuvanted Covid-19 booster in Europe, developed by
Sanofi
and
GSK
. The BARDA-funded vaccine, known as
VidPrevtyn
Beta
, contains a version of the spike protein found on the surface of the Beta variant of the coronavirus, and an adjuvant to strengthen the immune response.
While acknowledging that
Veru’s
potential drug for Covid-19 hospitalizations hit the mark on mortality in a small trial, and
may have enough for an EUA
with a confirmatory trial add-on, the FDA’s briefing documents ahead of an adcomm also pointed to uncertainties in the data. But the panel
voted narrowly against
the repurposed cancer drug, arguing the benefits do not outweigh the risks.
Agenus’
invariant natural killer T cell-focused spinout
MiNK Therapeutics
arrived at SITC with some early cancer data, but it also dropped
positive results of a Phase I/II study
of its lead candidate, made from those same rare immune cells, treating acute respiratory distress syndrome, a serious complication of Covid. Seeing that the drug boosted patients’ chance of survival, MiNK says it will push forward the program pending a contract with DARPA.
Novavax
is tempering its expectations
once again on Covid-19 vaccine sales, as it reported $725 million in Q3 and around 94 million doses administered so far. Despite falling demand for booster shots, though, it is forging ahead with its booster candidate to counter the Omicron variant and touting topline results from a Phase III trial.
CELL/GENE TX
Just when you thought
BioMarin
has completed the package on hemophilia A gene therapy
valoctocogene roxaparvovec
(
valrox
), execs put out word that the FDA has upped the ante one more time and hinted that
it may extend the review
to look at three-year-data — putting a damper on any lingering hopes for a Q1 approval by the PDUFA date next year.
Immunotherapy and oncology player
Fate Therapeutics
put out word that collaborator
ONO Pharmaceutical
is
exercising its option
for a preclinical HER2-targeting, off-the-shelf CAR-T cell therapy called
FT825
/
ONO-8250
. The pair will now jointly develop and commercialize the drug for the US and Europe, while ONO grabs exclusive rights for the rest of the world.
Verve Therapeutics
is running up against a regulatory wall as it looks to expand the clinical trial of its base editing therapy to the US. The FDA
placed the program
, which is designed to permanently turn off the PCSK9 gene in patients with dangerously high cholesterol levels, on clinical hold. Three patients have been dosed in New Zealand and the UK since July.
With all hands on deck to enroll the first patient for its lead sickle cell trial,
Beam Therapeutics
will pull back clinical plans
for a second base editing therapy aimed at sickle cell disease. While it had hoped to file an IND in 2022 for
BEAM-102
, which takes an alternative approach than
BEAM-101
, the biotech said it needs to focus while also researching new technologies to go with the drug.
DEALS
A few days after
Amgen
charted a Phase III map for an up-and-coming cardio drug, the biotech behind its development decided to cash out.
Arrowhead Pharmaceuticals
sold its royalty stake
in
olpasiran
, a siRNA drug developed using its RNAi tech, to
Royalty Pharma
for $250 million in upfront cash, plus another $160 million in milestones.
As it moves to position itself beyond pandemic stardom,
Moderna
is spidering out into a number of biotech spheres. In its latest move, Moderna is adding
another antibody discovery collaboration
— this time with
Harbour BioMed
through its new subsidiary
Nona
Biosciences
. Harbour sports a platform that specifically develops heavy chain-only antibodies. It will pay a small upfront of $6 million to explore packaging those antibodies in mRNA systems.
Little
Nordic Nanovector
announced the end of its journey
in a reverse merger
, roughly three months after announcing it would essentially sell itself for parts. It will be swallowed by another biotech based out of Norway,
APIM
Therapeutics
, which will unveil a new name at a later date. Moving forward, it will be working on approaches to boost responses to other common cancer immunotherapies.
In the wake of a report to sell off its European consumer health business,
Viatris
is continuing its plot to shift strategies with two acquisitions that beef up its ophthalmology portfolio. It will buy
Oyster Point Pharma
and
Famy Life Sciences
in deals valued
between $700 and $750 million
. The company says the two new subsidiaries could potentially add more than $1 billion in sales by 2028 — a figure that was viewed skeptically by analysts on the call.
Sanofi
dished out $21.5 million upfront
to partner with
Insilico
, marking the Big Pharma’s third major AI drug deal this year. The pact covers up to six undisclosed targets, with downstream milestones potentially adding up to $1.2 billion. The French pharma giant noted that the tie-up will boost discovery efforts out of its R&D center in China.
STARTUPS
Lipidio Pharmaceuticals
launched right before Covid-19 took the world by storm, initially focusing on metabolic indications. More than 2.5 years later, the biotech has added dermatology to that list and secured some of the industry’s most well-known investors — think
John Maraganore
and
Brett Saunders
—
for a Series A extension round
.
For patients with diabetic retinopathy, anti-VEGF injections to the eye are often the only non-surgical option to stave off vision loss. But a
Novo
-backed startup is joining the search for drugs that can be given orally.
Breye Therapeutics’
$4 million seed funding
should push its lead drug, one from
Zealand Pharma’s
shelves, into clinical testing.
With founders out of Mass General and Harvard,
Sensorium Therapeutics
wanted to take the next step in the mental health and CNS space with what it calls psychoactive drugs. And investors are now
pouring $30 million in Series A
cash into its approach of mining plants and fungi for potential treatments of anxiety and depression.
Can targeting a mitochondrial pathway previously thought to be undruggable crack the code in devastating neurodegenerative diseases, such as Parkinson’s and ALS? For
NRG
Therapeutics
, that’s the
£16 million question
. Its research, according to the two
GSK
vets behind it, has pinpointed a way to protect mitochondria from the hallmark neuronal damage seen in neurodegeneration. Funds will be used to get NRG through IND-enabling studies.
Two former Stanford researchers
nabbed a $41 million launch round
to learn the secrets of the “secretome.”
Juvena Therapeutics
intends to use the funds primarily to build out its map of secreted proteins and understand how they affect chronic conditions, while also advancing a handful of discovery-stage experimental drugs.
FINANCING
Tony Coles
set out to build “the premier neuroscience company” at
Cerevel
. And that means putting fundraising plans in place well in advance. Just weeks after tying the knot on a $599 million haul — from a dual stock sale and convertible debt arrangement — the biotech filed a statement with the SEC to
raise up to $900 million
over the next few years.
Kura Oncology
is set for a few more years,
thanks to some new partners
.
Bristol Myers
is investing $25 million into the biotech as an equity investment, while
Hercules Capital
is coming on board with a term loan facility worth $125 million. If maxed out, the funding will extend Kura’s runway into 2026.
Getting a fresh start after selling its CGRP portfolio to
Pfizer
,
Biohaven
reported in its Q3 earnings that it closed a public offering in late October to
raise $301.9 million
. The biotech didn’t necessarily need the cash — it had enough from the buyout — but some large funds wanted to invest, said CEO
Vlad
Coric
.
PHARMA
AstraZeneca
and
Merck
executives
are now raising concerns
about how President Biden’s new drug price negotiation law will impact cancer drug development moving forward as the clock for negotiations begins with the first approved indication. AstraZeneca’s
Pascal Soriot
went as far as to say that his company may no longer launch new cancer drugs in the US unless it’s for a large enough indication to keep that clock from starting too soon.
At the request of the FDA,
GSK
will restrict the second-line maintenance indication
for
Zejula
(
niraparib
) to only certain cancer patients with deleterious or suspected deleterious germline BRCA mutations (gBRCAmut). The decision is based on the FDA’s review of the final overall survival analysis of the Phase III trial that led to this approval in the first place.
Regeneron’s Libtayo
made it into the exclusive club of PD-(L) inhibitors approved, in combination with chemotherapy, as a frontline treatment for a broad swath of lung cancer patients. Based on Phase III overall survival data, the FDA
granted Libtayo an OK
in adult patients with advanced non-small cell lung cancer with no EGFR, ALK or ROS1 aberrations.
Weeks after celebrating the first cancer win for its
Imfinzi
and
Imjudo
duo,
AstraZeneca
is once again breaking out the party hats. The PD-L1/CTLA-4 combo
scored a label expansion
in metastatic non-small cell lung cancer alongside platinum-based chemotherapy. Just last month, the drugs won a nod in the most common type of liver cancer.
Seagen’s
top-selling drug just
scored another indication
, a few weeks after execs boosted their full-year sales expectations. The company’s
Takeda
-partnered antibody-drug conjugate
Adcetris
is now available to pediatric patients 2 years and older with previously untreated high-risk classical Hodgkin’s lymphoma, in combination with a standard-of-care chemotherapy regimen.
Following in the footsteps of the EU, the UK’s MHRA
signed off on
Sanofi
and
AstraZeneca’s
RSV antibody
nirsevimab
. It will be the first single-dose option for all newborns and infants during their first RSV season.
MARKETINGRX
Looking to get an oncologist’s attention with a branded drug message? Keep it short and simple, but don’t forget the data. That’s
some of the advice emerging from
ZoomRx’s
deep dive into oncology marketing messaging to healthcare professionals. Messages that contained 10-14 words were found to be the most effective.
October may be over, but
Merck
is continuing to drive its awareness efforts
around breast cancer — especially focused on the rare triple negative subtype and Black women who are disproportionately affected. Actress
Yvonne
Orji
, who also holds a master’s degree in public health, narrates the three-video docuseries at the center of “Uncovering TNBC,” where she interviews three Black women about their experiences.
More than half of people living with chronic obstructive pulmonary disease in the US are undiagnosed. It’s not a brand new problem, but it’s one
AstraZeneca
is shining a light on
with marketing and awareness efforts during November’s National COPD Awareness Month. The pharma giant is engaging leading pulmonologist
MeiLan
Han
, as a partner.
For
Reckitt
, the focus for COPD awareness month is on the other use of its well-known over-the-counter cough and cold remedy
Mucinex
: thinning and loosening mucus in chronic bronchitis patients. Its first-ever effort
aims at helping physicians identify
people with undiagnosed chronic lung disease.
Pharma and healthcare ads miss the mark on realistic portrayals of women,
a new study from
WPP
finds. Asked how they’re being depicted in healthcare ads versus the way they actually see themselves, many women don’t see themselves in those ads — but they want to. The most glaring disconnects were around weight, reproductive care and mental health.
Astellas
is highlighting the people behind its oncology efforts
with its latest corporate campaign. Shot in black-and-white, the “Changemakers” video series features some of the real Astellas Oncology employee scientists, researchers and business people talking about their passions and reasons for doing what they do. With the messages, Astellas is hoping to speak to physicians and healthcare providers.
Independent advertising agency
Klick Health
announced its first-ever global expansion this summer — and now it has
lined up its leadership
, with managing directors in Latin America, Europe, the Middle East and Africa, plus an Asia Pacific leader to be announced soon. The new leaders will be tasked with building regional and local offices.
J&J’s Janssen
detailed progress in the first year of its peripheral artery disease campaign, “Save Legs. Change Lives,” aimed at reaching Black Americans;
AstraZeneca
is looking to remove clinical trial challenges with a “hybrid” tech platform;
Eli Lilly
is set to launch its first-ever connected suite of diabetes products this year, hooking together an app, insulin pen and a “smart button” data keeper — You can learn about all these and
more in the MarketingRx roundup
.
FDA+
While Congress punted on adding new accelerated approval reforms to the user fee legislation, the FDA appears to be taking the matter into its own hands.
ADC Therapeutics
revealed, as part of its Q3 earnings report, that it’s
taking a step back to reevaluate
its experimental CD25-targeted antibody-drug conjugate after the FDA asked for a confirmatory trial to be “fully underway” prior to accelerated approval submission.
BrainStorm Cell Therapeutics’
first attempt to approach the FDA with its ALS treatment
has been slapped down
with a refusal to file letter from regulators. The move comes after the FDA, in a rare public slapdown, said in March 2021 that Phase III data for its NurOwn therapy were “not at all statistically significant.”
Building off President
Joe Biden’s
executive order from July 2021, the FDA and Patent and Trademark Office are looking
to forge a tighter bond
on everything from “skinny” generic drug labels to better training patent examiners. As part of building this closer relationship, the FDA and USPTO will hold a public listening session in January.
AstraZeneca’s
experimental asthma drug scored an
overwhelming thumbs up
from the FDA advisory committee for its use in adults. But when it came to adolescents and kids, the panel of external experts was less sure. The mixed votes could cast a shadow on the aspirations at AstraZeneca, which had proposed a broad label in its NDA filing for PT027.
With the growth in biologics spending, interchangeable biosimilars that can be substituted without a doctor’s note
will be key to increasing competition
, a top FDA official said at a conference — where officials also discussed key flexibilities that they can make around the development of such copycat drugs.
MANUFACTURING
Towards the end of the summer,
Pfizer
was facing the heat from a labor action at a manufacturing facility in western Australia as workers walked off the job in protest of what was seen as “substandard pay.” Now, another similar labor action in Australia
is turning up the heat even more
, with over 100 workers downing tools and demanding a pay rise.
As
Novartis
continues to reshape itself, the company is shuttering one of its gene therapy manufacturing sites in the US. The closure of a site in Libertyville, IL, a city to the northeast of Chicago, follows a “comprehensive manufacturing site network evaluation,” the company said. The decision
will cause 275 jobs to be axed
.
Following a 10-day inspection earlier this year, the FDA
sent a warning letter
with several pointed questions to a Phoenix-based site, which is run by
Abraxis Bioscience
and owned by
Bristol
Myers
Squibb
. According to regulators, it did not effectively implement corrective actions and preventive actions or adequately control its aseptic processing line and manufacturing operations.
In response to the FDA’s call on all drug manufacturers to improve the safety of the US drug supply and conduct risk assessments of products to detect potentially cancer-causing nitrosamine impurities, the generic drug industry
is pushing the agency to take a more
risk-based, scientific approach to the way it’s evaluating these impurities.
The FDA has had its eye on the pharmaceutical manufacturer
Lupin
for a while, and an inspection of a facility tasked with developing biosimilars brought to light
several quality control issues
. The 10-page Form 483 had a total of 18 observations, starting with that the aseptic monitoring for a filling and closing machine was inadequate.
The explosive growth in clinical cell therapy programs is driving
Charles River Laboratories’
next expansion. The outsourcing player
is planning to boost
its cell therapy manufacturing capabilities in Memphis, TN, adding nine processing suites and bringing the total number of suites to 23.
Global Healthcare Opportunities
, otherwise known as
GHO
Capital
, and
The Vistra Group
joined hands to acquire a controlling interest in the
Alcami
Corporation
; The CDMO
Wheeler Bio
kicked off construction on a manufacturing facility in Downtown Oklahoma City; DNA sequencing company
Illumina
launched a new solutions center in Dubai — check out what else you missed in the
Manufacturing roundup
.
DON’T MISS
In a groundbreaking first, researchers and doctors from the University of California San Francisco, Duke and the University of Ottawa treated a baby with Pompe disease, a debilitating genetic disease, while she was
still in her mother’s uterus
. The case, published in NEJM, is the first instance that an enzyme replacement therapy, a type of treatment used for Pompe and other lysosomal storage diseases, was given to an unborn child.
Faze Medicines
, which launched in 2020 with an $81 million Series A and a goal of developing a treatment for ALS and other neurodegenerative diseases through molecular condensates,
shutting its doors
, according to employee social media posts and a report in STAT.
Third
Rock
, an investor, said “the science did not progress sufficiently to meet our bar for further investment.”
Ipsen
announced a
positive late-stage readout
on
Onivyde
, which helped patients with pancreatic cancer live longer in a Phase III trial. But the biggest winner could be
Merrimack
Pharmaceuticals
, a biotech that shut down operations in 2019 after repeated failed attempts at getting another drug through the clinic.